Abcam, ab128876, Anti-FOXO1A (pT24)+FOXO3A (pT32)+FOXO4 (pT28)+FOXO6 (pT26) antibody

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal FOXO4/AFX phospho T32 antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR2314(2),
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
This antibody was developed as part of a collaboration with Tobais Dansen from the University of Utrecht in the Netherlands.
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FOXO1A FOXO4/AFX FOXO3A and Foxo6 are proteins that belong to the Forkhead box O (FOXO) transcription factors family known for their role in regulating gene expression linked to various cellular processes. These proteins including FOXO3A with a molecular weight of approximately 71 kDa are primarily expressed in multiple tissues such as the brain liver and adipose tissue. These transcription factors act mechanically by binding to specific DNA sequences to control the expression of genes involved in metabolism cell cycle and apoptosis.
Biological function summary
FOXO proteins influence numerous cellular functions through their role in gene transcription. They are often considered part of larger complexes interacting with various cofactors and other proteins to modulate gene expression. FOXO3A for example plays a role in cellular antioxidant defense energy metabolism and maintenance of cellular homeostasis. Their activity can be modulated by post-translational modifications such as phosphorylation which influences their localization between the cytoplasm and nucleus affecting their function.
Pathways
FOXO proteins are integral components of the insulin-signaling pathway and the PI3K/Akt pathway. Through these pathways they interact closely with proteins such as Akt and PI3K which regulate their activity and subcellular localization. The insulin pathway modulates metabolic processes and glucose homeostasis while the PI3K/Akt pathway is involved in cell survival and growth. Their regulatory functions highlight their adaptive response to environmental and internal cellular signals.
FOXO proteins link to conditions like cancer and diabetes. In cancer FOXO3A is often implicated in tumor suppression where its inactivation can lead to an increase in cell proliferation and survival. The loss or mutation of FOXO function may contribute to tumorigenesis. In diabetes FOXO proteins relate to insulin regulation and resistance impacting metabolic syndrome and glucose intolerance. The interplay with proteins like Akt during these diseases can alter their transcriptional activity highlighting their significance in disease progression and potential therapeutic targets.